Sirolimus treatment of left ventricular hypertrophy: who, and when? by Crespo-Leiro, María Generosa & Hermida-Prieto, Manuel
 European Heart Journal. 2008; 29(22): 2703-2704 
Sirolimus treatment of left ventricular hypertrophy: who, and 
when? 
Maria G. Crespo-Leiro
1
 and Manuel Hermida-Prieto
2
 
1 Heart Failure and Heart Transplantation Unit, Hospital Universitario A Coruña, La Coruña, Spain; and 
2 Instituto de Ciencias de la Salud, Universidad de A Coruña, La Coruña, Spain 
This editorial refers to ‘Sirolimus affects cardiomyocytes to reduce left ventricular mass in heart 
transplant recipients’† by S.S. Kushwaha et al., on page 2742 
The protein known as mammalian target of rapamycin (mTOR) plays vital roles in protein synthesis, 
and hence in growth and cell proliferation, including the proliferation of immune response cells and 
neoplastic cells. The paths through which it acts have two main branches that start from mTOR 
complexes known as mTORC1/RAPTOR and mTORC2/RICTOR. The former is inhibited by sirolimus 
(rapamycin), everolimus, and their analogues, while the latter is not. Despite not inhibiting 
mTORC2/RICTOR, the sirolimus family are known collectively as mTOR inhibitors, and also as 
proliferation signal inhibitors (PSIs).
1 
 
mTOR inhibitors are attractive for post-transplantation therapy because their antiproliferative 
properties appear to combine immunosuppression with reductions in the risk or progression of 
proliferative post-transplantation complications, notably malignancy
2
 and allograft vasculopathy.
3,4
 When 
replacing antimetabolites in triple therapy in conjunction with calcineurin inhibitors (CNIs) and steroids, 
mTOR inhibitors have been reported to decrease the progression of cardiac allograft vasculopathy without 
increasing the incidence of acute rejection;
4–6
 and as replacements or partial replacements of CNIs they 
have been found both to attenuate the progression of allograft vasculopathy after heart transplantation 
(HT)
7
 and to reduce the incidence of malignancy after kidney transplantation.
8 
 
Kushwaha et al.
9
 have presented results suggesting that mTOR inhibitors may actually bring about the 
reversion of another common life-threatening post-HT complication, left ventricular hypertrophy 
(LVH).
10
 In a retrospective study in which 83 patients with a CNI as primary immunosuppressor were 
compared over 1 year with 58 for whom a CNI was replaced with sirolimus because of nephrotoxicity 
and/or allograft vasculopathy, the authors found that LV mass index (LVMI) decreased significantly from 
99 to 93 g/m
2
 in the sirolimus group while increasing slightly in the CNI group, and that left atrial volume 
index, an indirect measure of diastolic function, decreased significantly in the sirolimus group while 
increasing significantly in the CNI group. Moreover, the reduction in LVMI was almost entirely found in 
the 13 sirolimus-treated patients with LVH at baseline, among whom average LVMI fell by 24 g/m
2
. 
These results are in keeping with reports that in mice sirolimus reduces overload-induced LVH and 
fibrosis, and reverses associated alterations of gene expression;
11,12
 and that in kidney transplant patients 
 with allograft nephropathy, replacement of CNIs with sirolimus may bring about the regression of LVH 
independently of blood pressure changes.
13 
 
Kushwaha et al. tentatively attribute the observed regression of LVH to the direct action of sirolimus 
on myocardium rather than to any influence on hypertension, the main cause of LVH in HT patients.
14
 
They base this conclusion on the fact that although blood pressure fell in the sirolimus group and not in 
the CNI group (doubtless because of the withdrawal of CNIs in the former), the blood pressure changes in 
the sirolimus group were not correlated with LVMI; and on the observation that the number of 
endomyocardial biopsy cells stained by a polyclonal antibody against the cell cycle inhibitor p27Kip1 
increased in a group of 22 sirolimus-treated patients but not in a group of nine CNI-treated patients. In 
this respect, one misses the presentation of data on whether the p27Kip1-positive cell count correlated 
with the degree of LVH regression. Also, although increased p27Kip1 synthesis is not entirely 
unexpected (being a known effect of mTOR inhibition),
15
 it is a pity that the results of labelling with 
polyclonal antibody were not backed up by reverse transcription–PCR or expression array studies. Such 
studies might have confirmed alteration of the complex pathway between mTOR and p27Kip1, and 
thrown light on whether alteration of other signalling pathways might also have been involved in the 
observed regression of LVH. Given the central physiological roles of mTOR, it is certainly on the cards 
that its inhibition has as yet unknown consequences,
16
 and that any such consequences may include 
effects that are relevant to LVH. 
 
Even if sirolimus does induce LVH regression in addition to its antitumoural, antivasculopathic, and 
immunosuppressive effects, it is not a panacea. As might be expected, given the very fundamental 
functions of mTOR, the administration of mTOR inhibitors has been associated with numerous adverse 
side effects with varying degrees of manageability, including hyperlipidaemia, defective wound healing, 
oedema, bacterial infections, acne, pneumonitis, and proteinuria.
17
 Together with the immunosuppressive 
action of mTOR inhibitors, these effects call for great caution to be exercised in regard to the tacit 
suggestion of Kushwaha et al. that sirolimus may be a valid therapeutic approach to LVH in non-
transplant patients. 
 
The renal effects of replacing CNIs with mTOR inhibitors are particularly controversial. Although 
mTOR inhibitors are not themselves nephrotoxic, and their substitution for CNIs therefore reduces renal 
insult, there have been reports that total withdrawal of CNIs increases the risk of kidney graft rejection,
18
 
while partial withdrawal is called into question by reports that mTOR inhibitors potentiate the 
nephrotoxicity of CNIs.
17
 Other studies have observed improved renal function without increased 
rejection risk in the total absence of CNIs,
3,19
 or that renal function improved when low-level CNI 
administration accompanied administration of an mTOR inhibitor. Since the increased rejection risk 
seems mainly to affect patients in their first post-transplant year, some authors have recommended that 
mTOR inhibitors be used in conjunction with low-level CNI administration during this period.
17 
 
Another factor to be taken into account is the possible desirability of administering mTOR inhibitors 
together with additional drugs that counteract some of the mechanisms by which the cell responds to 
mTOR inhibition. It is known that there is a negative feedback loop whereby inhibition of mTORC1 by 
sirolimus increases AKT activation, which tends to restore mTOR activity;
20
 and Carracedo et al.
21
 have 
recently reported that cancer patients exhibit a second negative feedback loop, with similar effects, 
involving the mitogen-activated protein kinase pathway. 
 
Kushwaha et al.'s findings open up exciting perspectives for the treatment of post-HT LVH. They call 
for more thorough evaluation in randomized trials that allow overall assessment of the pros and cons of 
mTOR inhibitor therapy. mTOR inhibitors certainly seem to have a role to play in the management of 
transplant patients; in the coming years, further research must characterize that role more fully. 
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